With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

Just weeks after Astellas agreed to pay Aquinox Pharmaceuticals $25 million upfront for Asian rights to their lead drug rosiptor, the little biotech says their Phase III trial was a complete disaster, leaving nothing to salvage.

David Main

CEO David Main didn’t sugarcoat it. No matter how hard they studied the data, the interstitial cystitis drug clearly couldn’t beat a placebo. He said:

We have conducted a number of sensitivity, subpopulation, and secondary endpoint analyses and none demonstrate a benefit of rosiptor over placebo.

Investors betting on a key success here clearly weren’t happy. Aquinox’s shares $AQXP were swiftly decimated, diving 85%.

The Vancouver-based biotech had hoped for better, recruiting 433 patients suffering from interstitial cystitis/bladder pain syndrome for the study, which had the same design as Phase II.

After burying the drug program, and watching its market cap shrivel, Main says it’s time to study what kind of strategic alternatives remains open. There is a mid-stage study underway for the same drug — a small molecule activator of SHIP1 — in chronic prostatitis/chronic pelvic pain syndrome. But virtually all of its eggs were in the one drug basket.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->